Treating diabetic retinopathy (DR) is still a significant challenge for clinicians and remains a leading cause of blindness worldwide. NovaGo Therapeutics is developing a human antibody therapy ...

The following is a summary of “Evaluation of macular retinal oximetry across different levels of diabetic retinopathy: a cross sectional study,” published in the January 2025 issue of Ophthalmology by ...

Background: This study was performed to assess the prevalence of dry eye syndrome and diabetic retinopathy (DR ... included 34 patients (17.1%) with mild non proliferative DR (NPDR), 34 patients ...

The companies, which are both from Alphabet’s stable of tech firms, have been using the technology to screen for diabetic retinopathy ... Nikon and its subsidiary Optos to see if it can be ...